Measurement of the distance between tumor micro-foci and gross tumor in rectal cancer pathological specimens: implication on margin distance of clinical target volume treated with high-dose radiotherapy for rectal cancer
Open Access
- 8 July 2024
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 29 (10) , 1491-1499
Abstract
Purpose: To measure the micro-foci distance away from gross tumor and to provide reference to create the clinical target volume (CTV) margin for boost radiotherapy in rectal adenocarcinoma. Methods: Twenty-eight rectal cancer surgical specimens of only total mesorectal excision were collected. The pathological specimens were retrospectively measured, and the nearest distance between the tumor micro-foci and gross tumor was microscopically measured. The “in vivo–in vitro” retraction factor was calculated as the ratio of the deepest thickness laterally and the vertical height superior/inferiorly of the rectal tumor measured in MRI and those measured in immediate pathological specimens. The retraction factor during pathological specimen processing was calculated as the distance ratio before and after dehydration in the lateral, superior, and inferior sides by the “knot marking method.” The distances of tumor micro-foci were individually corrected with these two retraction factors. Results: The mean “in vivo–in vitro” tumor retraction factors were 0.913 peripherally and 0.920 superior/inferiorly. The mean tumor specimen processing retraction factors were 0.804 peripherally, 0.815 inferiorly, and 0.789 superiorly. Of 28 patients, 14 cases (50.0%) had 24 lateral micro-foci, 8 cases (28.6%) had 13 inferior micro-foci, and 7 cases (25.0%) had 19 superior micro-foci. The 95th percentiles of the micro-foci distance for 28 patients were 6.44 mm (peripheral), 5.54 mm (inferior), and 5.42 mm (superior) after retraction correction. Conclusion: The micro-foci distances of 95% of rectal adenocarcinoma patients examined were within 6.44 mm peripherally, 5.54 mm inferiorly, and 5.42 mm superiorly. These findings provide reference to set the boost radiotherapy CTV margin for rectal cancer.Keywords
This publication has 25 references indexed in Scilit:
- Microscopic intramural extension of rectal cancer after neoadjuvant chemoradiation: A meta-analysis based on individual patient dataRadiotherapy and Oncology, 2020
- Intensity-Modulated Radiotherapy With a Simultaneous Integrated Boost in Rectal CancerClinical Oncology, 2020
- Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patientsHuman Pathology, 2016
- Watch and Wait: Is Surgery Always Necessary for Rectal Cancer?Current Treatment Options in Oncology, 2016
- Complete Response after Chemoradiotherapy in Rectal Cancer (Watch-and-Wait): Have we Cracked the Code?Clinical Oncology, 2016
- Peritumoral deposits as an adverse prognostic indicator of colorectal cancerThe American Journal of Surgery, 2014
- Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Evaluation of microscopic tumor extension in non–small-cell lung cancer for three-dimensional conformal radiotherapy planningInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000